Investing in our common stock involves a high degree of risk. Startups Act of 2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. We are an emerging growth company as the term is used in the Jumpstart Our Business On The NASDAQ Global Market under the symbol ∺AVL. We expect the initial public offering price to be between $13.00 and $15.00 per share. This is our initial public offering and no public market currently exists for our common stock. Subject to completion, dated July 21, 2014Ĭommon stock. Jurisdiction where the offer or sale is not permitted. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any These securities until the registration statement filed with the Securities and Exchange Commission is effective. The information in this preliminary prospectus is not complete and may be changed. Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective inĪccordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. The amount paid in connection with this filing for the aggregate registration fee of $11,998 includes $11,109 previously paid and $889 for the additional amount of $6,900,000 of securities included in this amendment to Includes shares that the underwriters have the option to Includes 810,000 shares that the underwriters have the option to purchase.Įstimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended. X (Do not check if a smaller reporting company)Ĭommon Stock, $0.0001 par value per share See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. Non-accelerated filer, or a smaller reporting company. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for theĪmendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, (Address, including zip code, and telephone number, including area code, of registrants principal executive offices)Īddress, including zip code, and telephone number, including area code, of agent for service)Īpproximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement. (Exact name of registrant as specified in its charter) 3 to Form S-1 Table of ContentsĪs filed with the Securities and Exchange Commission on July 21, 2014. Additionally, his focus includes development and evaluation of novel medical device technologies, imaging technologies, surgical equipment (including surgical robots), and drug delivery systems.Amendment No. Schwartz’s primary research areas include early diagnosis and treatment of diseases such as macular degeneration, retinopathy of prematurity (ROP), and diabetic eye disease. He received his medical degree from the University of Southern California (USC) School of Medicine, completed an Internship at the USC Hospital in Medicine, Surgery and Anesthesia, a Residency in Ophthalmology at UCLA School of Medicine-Jules Stein Eye Institute, and a Fellowship in Retina/Uveitis at the UCL Institute of Ophthalmology, Moorfields Eye Hospital. Steven Schwartz currently serves as Ahmanson Professor of Ophthalmology, Professor-in-Residence of Ophthalmology, Chief of Retina Division, Director for Diabetic Eye Disease and Retinal Vascular Center, and Director of the Ophthalmic Photography Clinical Laboratory for Jules Stein Eye Institute at the University of California, Los Angeles (UCLA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |